PRESS-NEWS.org - Press Release Distribution
PRESS RELEASES DISTRIBUTION

Scientists discover how leukemia cells exploit 'enhancer' DNA elements to cause lethal disease

Discovery also reveals how a drug, now in multiple human trials, halts production of Myc protein and stops progression of AML

2013-11-27
(Press-News.org) Contact information: Jaclyn Jansen
jjansen@cshl.edu
516-367-8455
Cold Spring Harbor Laboratory
Scientists discover how leukemia cells exploit 'enhancer' DNA elements to cause lethal disease Discovery also reveals how a drug, now in multiple human trials, halts production of Myc protein and stops progression of AML

Cold Spring Harbor, NY – A team of researchers at Cold Spring Harbor Laboratory (CSHL) has identified a leukemia-specific stretch of DNA called an enhancer element that enables cancerous blood cells to proliferate in Acute Myeloid Leukemia (AML), a devastating cancer that is incurable in 70% of patients. Just as important, the findings offer a mechanistic insight into how a new class of promising drugs – one version of which is already in human clinical trials – appears to halt the growth of cancer cells so effectively.

The research, appearing today in Genes & Development and led by CSHL Assistant Professor Chris Vakoc, centers on the way a cancer-promoting gene is controlled. When this oncogene, called Myc, is robustly expressed, it instructs cells to manufacture proteins that contribute to the uncontrolled growth that is cancer's hallmark. The Myc oncogene is also implicated in many other cancer types, adding to the significance of the new finding.

Vakoc's team discovered an enhancer element that controls the Myc oncogene specifically in leukemia cells. Unlike many other DNA-based gene regulators, this string of DNA "letters" is nowhere near the Myc gene it regulates. In fact, it's far away, and in order to affect the Myc gene, some other element – unknown, prior to these experiments -- has to bring the enhancer in proximity to the gene. In their experiments, the team found a protein complex, called SWI/SNF, that links the enhancer element and the Myc gene it activates.

"The enhancer elements we discovered are 1.7 million DNA bases away from their target gene, Myc," says Vakoc. "But we were able to show that this long stretch of the genome is bent and looped in the cell nucleus in such a way that the remote enhancer segment literally touches the distant segment harboring the cancer gene. Our results suggest that this regulatory conformation fuels the uncontrolled growth of cancer cells and may explain why the Myc gene is so uniquely sensitive to targeting with a new class of drugs being developed for leukemia." The Vakoc lab in 2011 discovered a novel therapeutic strategy to shut off Myc in cancer, an approach now being tested in phase 1 clinical trials.

Vakoc and Junwei Shi, a graduate student in the Vakoc lab and lead author on the new paper, identified the SWI/SNF protein complex in an experiment that searched for proteins that stop AML disease progression while still allowing healthy cells to grow normally. In collaboration with Professor Richard Young from the Whitehead Institute, they worked to determine where in the genome SWI/SNF attaches to DNA. That's when they discovered its binding to the enhancer element located 1.7 million bases away from the Myc gene.

Intriguingly, this enhancer occupies a spot in the genome that Vakoc's team found was most often abnormally duplicated in AML cells. "We usually look for duplicated genes in cancer," Vakoc says. "But this is the first time we've ever seen DNA for an enhancer, rather than for a gene, being a common duplication in a cancer type."

In mechanical terms, how does SWI/SNF exert control over Myc? Vakoc collaborated with CSHL Professor David Spector to determine how the DNA at the Myc gene is folded and organized within the nucleus. Surprisingly, when the SWI/SNF complex binds to the enhancer, it reorganizes DNA in the nucleus so that this region comes in contact with Myc, enabling it to regulate Myc expression.

This happens only in leukemia, meaning the enhancer is unique. The work thus identifies an important mechanism that enables leukemia to proliferate. This in turn explains how leukemia drugs that have recently been discovered exert their beneficial effect. One notable example is a drug called JQ1 that Vakoc identified in 2011 as an inhibitor of a cancer-promoting protein called Brd4, which plays a pivotal role in the AML disease process. JQ1 likely blocks the interaction between Brd4 and the same enhancer element identified in the newly published research. This then sets off changes in the cell nucleus that prevent Myc expression.

"SWI/SNF is a drug target that we are now actively pursuing, but this study goes far beyond this result, providing fundamental insight into how cancer cells exert control over genes," Vakoc says. "By enabling us to understand the mechanism behind effective anti-leukemia drugs, our findings should allow us to design better therapeutics that will overcome drug resistance and be as safe as possible."



INFORMATION:

This work was supported by Starr Cancer Consortium, Edward P. Evans Foundation, the Martin Sass Foundation, the F.M. Kirby Foundation, Alex's Lemonade Stand Foundation, the Laurie Strauss Foundation, the V Foundation, the Burroughs-Wellcome Fund, Cold Spring Harbor Laboratory National Cancer Institute Cancer Center Support grant, Leukemia and Lymphoma Society Specialized Center of Research (SCOR) grant, and National Institutes of Health grants from NCI and NIGMS.

"Role of SWI/SNF in acute leukemia maintenance and enhancer-mediated Myc regulation" appears online ahead of print in Genes & Development on November 26, 2013. The authors are: Junwei Shi, Warren Whyte, Cinthya Zepeda-Mendoza, Joseph Milazzo, Chen Shen, Melanie Eckersley-Maslin, Jae-Seok Roe, Jessica Minder, Fatih Mercan, Eric Wang, Amy Campbell, Shinpei Kawaoka, Sarah Shareef, Zhu Zhu, Jude Kendall, Matthias Muhar, Christian Haslinger, Ming Yu, Robert Roeder, Michael Wigler, Gerd Blobel, Johannes Zuber, David Spector, Richard Young, and Christopher Vakoc. The paper can be obtained online at: http://genesdev.cshlp.org.

About Cold Spring Harbor Laboratory Founded in 1890, Cold Spring Harbor Laboratory (CSHL) has shaped contemporary biomedical research and education with programs in cancer, neuroscience, plant biology and quantitative biology. CSHL is ranked number one in the world by Thomson Reuters for the impact of its research in molecular biology and genetics. The Laboratory has been home to eight Nobel Prize winners. Today, CSHL's multidisciplinary scientific community is more than 600 researchers and technicians strong and its Meetings & Courses program hosts more than 12,000 scientists from around the world each year to its Long Island campus and its China center. For more information, visit http://www.cshl.edu.



ELSE PRESS RELEASES FROM THIS DATE:

Kessler stroke researchers explore five new avenues for rehabilitation research

2013-11-27
Kessler stroke researchers explore five new avenues for rehabilitation research Treatments based on behavioral or non-invasive physiological stimulation show greatest potential West Orange, NJ. November 26, 2013. Because the concept of permanent neurological ...

Health insurance increases preventive care but not risky behaviors

2013-11-27
Health insurance increases preventive care but not risky behaviors (SACRAMENTO, Calif.) -- People with health insurance are more likely to use preventive services such as flu shots and health screenings to reduce their risk of serious ...

National study finds donor age not a factor in most corneal transplants

2013-11-27
National study finds donor age not a factor in most corneal transplants (SACRAMENTO, Calif.) — Ten years after a transplant, a cornea from a 71-year-old donor is likely to remain as healthy as a cornea from a donor half that age, and ...

A celebration of a Persian mystic leads to better understanding of dynamics

2013-11-27
A celebration of a Persian mystic leads to better understanding of dynamics James Hanna likes to have fun with his engineering views of physics. So when he and his colleague Jemal Guven visited their friend Martin Michael Müller in France on a rainy, dreary day, the three ...

Shortage of rheumatologists -- In some US regions closest doctor may be 200 miles away

2013-11-27
Shortage of rheumatologists -- In some US regions closest doctor may be 200 miles away A novel study published in the American College of Rheumatology (ACR) journal, Arthritis & Rheumatism, shows that smaller micropolitan areas of the U.S.—those with less than 50,000 people—have ...

Negative BRCA testing may not always imply lowered breast cancer risk

2013-11-27
Negative BRCA testing may not always imply lowered breast cancer risk PHILADELPHIA — Women who are members of families with BRCA2 mutations but who test negative for the family-specific BRCA2 mutations are still at greater risk for developing ...

2-way traffic enables proteins to get where needed, avoid disease

2013-11-26
2-way traffic enables proteins to get where needed, avoid disease Augusta, Ga. - It turns out that your messenger RNA may catch more than one ride to get where it's going. Scientists have found that mRNA may travel one way down a cell, ...

When the living and the deceased don't agree on organ donation

2013-11-26
When the living and the deceased don't agree on organ donation All 50 states and the District of Columbia have adopted the 2006 Revised Uniform Anatomical Gift Act (UAGA) or enacted similar legislation giving individuals the "First Person Authorization" ...

Lowering stand density reduces mortality of ponderosa pine stands

2013-11-26
Lowering stand density reduces mortality of ponderosa pine stands REDDING, Calif.—As trees grow larger in even-aged stands, competition develops among them. Competition weakens trees, as they contend for soil moisture, ...

Electronic cigarettes: New route to smoking addiction for adolescents

2013-11-26
Electronic cigarettes: New route to smoking addiction for adolescents E-cigarettes have been widely promoted as a way for people to quit smoking conventional cigarettes. Now, in the first study of its kind, UC San Francisco researchers ...

LAST 30 PRESS RELEASES:

Fig trees convert atmospheric CO2 to stone

Intra-arterial tenecteplase for acute stroke after successful endovascular therapy

Study reveals beneficial microbes that can sustain yields in unfertilized fields

Robotic probe quickly measures key properties of new materials

Climate change cuts milk production, even when farmers cool their cows

Frozen, but not sealed: Arctic Ocean remained open to life during ice ages

Some like it cold: Cryorhodopsins

Demystifying gut bacteria with AI

Human wellbeing on a finite planet towards 2100: new study shows humanity at a crossroads

Unlocking the hidden biodiversity of Europe’s villages

Planned hydrogen refuelling stations may lead to millions of euros in yearly losses

Planned C-sections increase the risk of certain childhood cancers

Adults who have survived childhood cancer are at increased risk of severe COVID-19

Drones reveal extreme coral mortality after bleaching

New genetic finding uncovers hidden cause of arsenic resistance in acute promyelocytic leukemia

Native habitats hold the key to the much-loved smashed avocado’s future

Using lightning to make ammonia out of thin air

Machine learning potential-driven insights into pH-dependent CO₂ reduction

Physician associates provide safe care for diagnosed patients when directly supervised by a doctor

How game-play with robots can bring out their human side

Asthma: patient expectations influence the course of the disease

UNM physician tests drug that causes nerve tissue to emit light, enabling faster, safer surgery

New study identifies EMP1 as a key driver of pancreatic cancer progression and poor prognosis

XPR1 identified as a key regulator of ovarian cancer growth through autophagy and immune evasion

Flexible, eco-friendly electronic plastic for wearable tech, sensors

Can the Large Hadron Collider snap string theory?

Stuckeman professor’s new book explores ‘socially sustainable’ architecture

Synthetic DNA nanoparticles for gene therapy

New model to find treatments for an aggressive blood cancer

Special issue of Journal of Intensive Medicine analyzes non-invasive respiratory support

[Press-News.org] Scientists discover how leukemia cells exploit 'enhancer' DNA elements to cause lethal disease
Discovery also reveals how a drug, now in multiple human trials, halts production of Myc protein and stops progression of AML